A novel product for tendinopathy treatment

NIH RePORTER · NIH · R44 · $20,300 · view on reporter.nih.gov ↗

Abstract

Project Summary Tendinopathy is a tendon disorder characterized by tendon deterioration that often leads to tendon rupture, and is associated with pain, swelling and impaired performance. There is currently no cure for tendinopathy. Therefore, there is an urgent need for effective treatments for tendinopathy. The parent award is focused on testing the TenoGen, the product to be developed, exerts a therapeutic effect in mitigating tendinopathy pathology and relieving tendinopathy-related pain and symptoms with no or minimal adverse effects. The purpose of this supplement project is to provide support for an underrepresented researcher to participate and contribute to the R&D of TenoGen within the scope of the parent study. The supplement study will focus on establishing the transcriptome profile of TenoGen treatment using state-of-the-art transcriptomic RNA sequencing (RNA-seq) and bioinformatics technologies. Successful completion of the proposed supplement project is expected to not only provide additional data to accelerate for the R&D and commercialization of TenoGen, but also provide valuable support and an unique opportunity for the candidate’s career development. 1

Key facts

NIH application ID
10306057
Project number
3R44AG056246-02A1S1
Recipient
NEW YORK/R&D/CTR/TRANSLATIONAL MED/THER
Principal Investigator
David T Fung
Activity code
R44
Funding institute
NIH
Fiscal year
2021
Award amount
$20,300
Award type
3
Project period
2017-09-15 → 2022-05-31